期刊文献+

氯-IB-MECA合成的研究进展

Research Progress in Synthesis of 2-Cl-IB-MECA
下载PDF
导出
摘要 2-氯-N6-(3-碘苄基)腺苷-5'-N-甲基尿嘧啶(氯-IB-MECA)是由Can-Fite公司开发的具有选择性的A_(3)腺苷受体激动剂,可同时治疗非酒精性脂肪性肝病、非酒精性脂肪性肝炎和肝细胞癌,具有广阔的市场前景。根据起始原料的不同对氯-IB-MECA合成方法进行了系统讨论。方法1以1-O-甲基-β-D-呋喃核糖苷为起始原料,经选择性羟基保护、氧化反应、酯化反应、酰胺化、酸化及脱保护得到氯-IB-MECA。方法2以2-乙酰氧基-5-((苯甲酰氧基)甲基)四氢呋喃-3,4-二基二苯甲酸酯为原料,经Vorbruggen糖苷化反应、亲核取代反应、保护基交换、氧化反应、羧酸酰胺化得到氯-IB-MECA。方法3以四乙酰核糖为原料,经亲核取代反应、脱乙酰基、邻二羟基保护、伯醇氧化、羧酸酰胺化和水解反应得到氯-IB-MECA。方法4以β-D-呋喃呋喃糖醛酸甲酯三乙酸酯为原料,经亲核取代、酯基酰胺化和脱乙酰基后得到氯-IB-MECA。经过比较认为,方法4原料易得,合成步骤少,反应和分离条件温和,收率高,更适合氯-IB-MECA的工业化生产。 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluracil(2-Cl-IB-MECA)is a selective A3 adenosine receptor agonist developed by Can-Fite company,which can simultaneously treat non-alcoholic fatty liver disease,non-alcoholic steatohepatitis,and hepatocellular carcinoma,and has broad market prospects.The synthesis methods of 2-Cl-IB-MECA are systematically discussed based on different starting materials.Method 1 uses methylβ-D-ribofuranoside as a starting material to obtain 2-Cl-IB-MECA by selective hydroxyl protection,oxidation,esterification,amidation,acidification,nucleophilic substitution and deprotection.Method 2 uses 2-acetoxy-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyldibenzoate as a starting material to form 2-Cl-IB-MECA through Vorbruggen glycosylation reaction,nucleophilic substitution,protective group exchange,oxidation reaction,and amidation of carboxylic acid.Method 3 employs tetraacetylribose as a starting material,through nucleophilic substitution,deacetylation,1,2-dihydroxy protection,oxidation of primary alcohol,amidation of carboxylic acid,and hydrolysis to produce 2-Cl-IB-MECA.Method 4 employsβ-D-ribofuranuronic acid methyl ester triacetate as a starting material,through nucleophilic substitution,amidation of ester,and deacetylation to generate 2-Cl-IB-MECA.After comparison,method 4 is considered to be more suitable for industrial production of 2-Cl-IB-MECA due to the easy availability of starting materials,fewer synthetic steps,mild reaction and separation conditions and high yield.
作者 史楚奇 王刚 傅晶 邓惠文 尹传奇 SHI Chuqi;WANG Gang;FU Jing;DENG Huiwen;YIN Chuanqi(School of Chemistry and Environmental Engineering,Wuhan Institute of Technology,Wuhan 430205,China)
出处 《武汉工程大学学报》 CAS 2023年第3期237-242,共6页 Journal of Wuhan Institute of Technology
基金 湖北省教育厅自然科学基金(B2019055)。
关键词 2-氯-N6-(3-碘苄基)腺苷-5'-N-甲基尿嘧啶 A_(3)腺苷受体激动剂 酰胺化 亲核取代 Vorbruggen糖苷化反应 2-Cl-IB-MECA A_(3)adenosine receptor agonist amidation nucleophilic substitution Vorbruggen glycosylation reaction
  • 相关文献

参考文献4

二级参考文献68

  • 1陈家旭,陈青红,徐洪雁,赵歆,胡立胜,万霞,支楠.肝郁证候宏观辨证标准的文献计量学研究[J].北京中医药大学学报,2004,27(4):1-4. 被引量:41
  • 2杨文明,陈彪,鲍远程,杨兴涛,汪美霞.肝郁证实验研究概览[J].中国中医药信息杂志,2004,11(12):1125-1127. 被引量:11
  • 3武嫣斐,王素萍,孙健民,魏俊妮.原发性肝癌中医证型临床分布及证型标准[J].山西中医学院学报,2007,8(2):21-23. 被引量:24
  • 4Fredholm BB.Abbrachio MP,Burnstoek C,et al.Nomenculture and classification of purinoceptors[J].Pharmacol Rer,1994,46(2):143-156.
  • 5Fishman P,Madi L,Bar-Yehuda S,et al.Evidence far involvement of Wnt signalling pathway in IB-MECA mediated suppression of melamoma cells[J].Oncogene,2002,21 (6):4060-4064.
  • 6Fredholm BB,Ijzerman AP,Jacobson KA,et al.International Union of Pharmacology 2001:XXV.Nomenclature and classification of adenosine receptors[J].Pharmacol Rer,2001,53(4):527-552.
  • 7Bar-Yehuda S,Madi L,Barak D,et al.Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation:a new class of myeloprolective agents[J].Exp Hematol,2002,30(12):1390-1398.
  • 8Bar-Yehuda S,Madi L,Silberman D,et al.CF101,An agonist to the A3 adenosine receptor,enhances the chemotherapeutic effect of 5-Fluorouracil in a colon carcinoma murine model[J].Neoplasia,2005,7(1):85-90.
  • 9Schulte G,Fredholm BB.Human adenosine A1,A2A,A2B,and A3 receptors expressed in Chinese hamster ovary cells all mediate the phosphory-lation of extracellular-regulated kinase 1/2[J].Mol Pharmacol,2000,58 (3):477-482.
  • 10Duann P,Ho TY,Desai BD,et al.Mesangial cell apoptosis induced by stimulation of the adenosine A3 receptor:signaling and apoptotic events[J].J Intestig Med,2005,53 (1):37-43.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部